MTRNR2L13: A Potential Drug Target and Biomarker (G100463500)

Target Name: MTRNR2L13

NCBI ID: G100463500

MTRNR2L13

Other Name(s): MT-RNR2 like 13 | HN13 | MT-RNR2 like 13 (pseudogene)

MTRNR2L13: A Potential Drug Target and Biomarker

MTRNR2L13, also known as interleukin-18 (IL-18), is a protein that is expressed in various tissues throughout the body. It is a key regulator of inflammation and immune responses, and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In recent years, researchers have been interested in using MTRNR2L13 as a drug target or biomarker for the development of new therapies.

The MTRNR2L13 protein is composed of 254 amino acids and has a molecular weight of 31 kDa. It is expressed in a variety of tissues, including the brain, spleen, heart, kidneys, and gastrointestinal tract. It is highly expressed in the liver and has been shown to be involved in the regulation of inflammation, immune responses, and cell death.

One of the key functions of MTRNR2L13 is its role in the regulation of cytokine production. Cytokines are small signaling proteins that are released by cells in response to specific stimuli, such as bacteria or viruses. These proteins help to coordinate the immune response and play a key role in the regulation of inflammation. MTRNR2L13 is shown to be involved in the production and regulation of several cytokines, including IL-12, IL-18, and IL-23.

In addition to its role in cytokine regulation, MTRNR2L13 is also involved in the regulation of cell death. Studies have shown that MTRNR2L13 is involved in the regulation of cell apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. This is important for maintaining tissue homeostasis and for the development and maintenance of tissues.

The potential drug target for MTRNR2L13 is its role in the regulation of inflammation and immune responses. MTRNR2L13 has been shown to play a key role in the regulation of T cell development and function, as well as the regulation of inflammation. It is also involved in the regulation of cytokine production and cell death, which are both important for the regulation of the immune response.

One of the potential benefits of targeting MTRNR2L13 as a drug target is its potential to treat a variety of conditions that are characterized by inflammation or immune dysfunction. For example, MTRNR2L13 has been shown to be involved in the regulation of the immune response to cancer, and is therefore a potential target for cancer therapies. It is also involved in the regulation of neurodegenerative diseases, and may be a potential target for therapies aimed at treating these conditions.

Another potential benefit of targeting MTRNR2L13 as a drug target is its potential to be used in a once-daily dosing regimen. MTRNR2L13 is expressed in most tissues of the body and is highly stable, which makes it a potential candidate for use in a once-daily dosing regimen. This is important because once-daily dosing regimens are often preferred by patients, as they reduce the number of drug interactions and side effects.

In conclusion, MTRNR2L13 is a protein that is involved in the regulation of inflammation and immune responses. Its potential drug target status and its potential to be used in a once-daily dosing regimen make it an attractive target for further research and development. Further studies are needed to fully understand the role of MTRNR2L13 in the regulation of inflammation and immune responses, and to determine its potential as a drug

Protein Name: MT-RNR2 Like 13 (pseudogene)

Functions: Plays a role as a neuroprotective and antiapoptotic factor

The "MTRNR2L13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRNR2L13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets